Skip to main content
SpringerLink
Log in

99mTc-PSMA Left Behind: a Call for Collaboration

  • Letter to editor
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig.1

Data Availability

Please contact the corresponding author for data requests.

References

  1. Osayande E, Carika F, Gerrit E. Technetium 99m PSMA superscan mimicking a bone scan gone wrong. Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s13139-022-00749-3.

    Article  Google Scholar 

  2. Moghadam SZ, Askari E, Divband G, Shakeri S, Aryana K. Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: a single center study. Rev Esp Med Nucl Imagen Mol. 2021. https://doi.org/10.1016/j.remnie.2021.05.005.

    Article  Google Scholar 

  3. Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, et al. Intraindividual comparison of 99mTc-methylene diphosphonate and prostate-specific membrane antigen ligand 99mTc-MIP-1427 in patients with osseous metastasized prostate cancer. J Nucl Med. 2018;59:1373–9.

    Article  CAS  Google Scholar 

  4. Aryana K, Salek R, Divband G. 177Lu-prostate-specific membrane antigen super scan and good response even after 1 cycle of radioligand therapy. Clin Nucl Med. 2018;43:273–5.

    Article  Google Scholar 

  5. Novartis (2022) Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer. In: Novartis media releases. 2022. https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Accessed 20 Apr 2022.

  6. Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, et al. 99mTc-PSMA SPECT/CT versus 68Ga-PSMA PET/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2021;46:68–74.

    Article  Google Scholar 

  7. Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, et al. Radiation dosimetry of 99mTc-PSMA I&S: a single-center prospective study. J Nucl Med. 2021;62:1075–81.

    Article  Google Scholar 

  8. Albalooshi B, Al Sharhan M, Bagheri F, Miyanath S, Ray B, Muhasin M, et al. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol. 2020;8:1–7.

    PubMed  PubMed Central  Google Scholar 

  9. Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

    Article  CAS  Google Scholar 

  10. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, et al. Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. Eur Urol. 2020;78:148–54.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Center, Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

    Soroush Zarehparvar Moghadam

  2. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Emran Askari & Kamran Aryana

Authors
  1. Soroush Zarehparvar Moghadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emran Askari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kamran Aryana
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SZM proposed writing the letter. EA wrote the initial draft. Material collection and analysis was performed by SZM and EA. KA is responsible for revision of the final draft. All authors read and accepted the final version of the manuscript.

Corresponding author

Correspondence to Kamran Aryana.

Ethics declarations

Ethical Statement

The case presented in this study is a part of a trial approved by ethics committee of Mashhad University of Medical Sciences. (IR.MUMS.fm.REC.1396.414).

Informed Consent

Written informed consent was obtained from the patient.

Competing Interests

Soroush Zarehparvar Moghadam, Emran Askari and Kamran Aryana declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moghadam, S.Z., Askari, E. & Aryana, K. 99mTc-PSMA Left Behind: a Call for Collaboration. Nucl Med Mol Imaging 56, 218–219 (2022). https://doi.org/10.1007/s13139-022-00753-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-022-00753-7

Search

Navigation